Faculty profile

Christian Steidl

ResearcherExperimental TherapeuticsUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Christian Steidl

Researcher

Experimental Therapeutics

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
68 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.
Principal investigator on 9 research grants (9 CIHR), most recently in 2024.
Supervised 6 trainees who won CIHR awards, most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

179

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Pathogenesis Lymphoma Genomics Biomarkers Gene Editing Gene Mutations Targeted Therapy Tumour Microenvironment

Latest papers

Non-canonical NF-κB drives a fate switch from germinal center to early effector B cells.
iScience · 2026
HNRNPU mutations redirect cell cycle control to E2F in MYC-driven lymphomas.
Blood advances · 2026
EpiATLAS - a reference for human epigenomic research.
bioRxiv : the preprint server for biology · 2026

All 179 publications

Latest funding

Cellular ecosystems of nodular lymphocyte predominant Hodgkin lymphoma
CIHR · 2024 · Nominated PI
$1,147,500
Cytokine receptor common beta chain alterations in mediastinal lymphomas
CIHR · 2023 · Nominated PI
$1,048,050
Development of second-generation radiopharmaceuticals targeting the C-X-C chemokine receptor 4 for imaging and therapy of hematological cancers
CIHR · 2022 · Co-investigator
$860,626

All 20 grants and awards

From the 150 most recent of 179 publications.

Non-canonical NF-κB drives a fate switch from germinal center to early effector B cells.

Nawaz W, Fong A, Cardoso MP, Tang J, Zhao J, Li MY, Rai S, Beresford A, Alduaij W, Boyle M, Steidl C, Scott DW, Venturutti L

iScience2026

DOI: 10.1016/j.isci.2026.116917 PMID: 42540498

HNRNPU mutations redirect cell cycle control to E2F in MYC-driven lymphomas.

Qureshi QUA, Coyle KM, Brown C, Thomas N, Collinge B, Dreval K, Steidl C, Scott DW, Audas TE, Morin RD

Blood advances2026

DOI: 10.1182/bloodadvances.2025019135 PMID: 42126254

EpiATLAS - a reference for human epigenomic research.

International Human Epigenome Consortium, Manz Q, Bilenky M, Hecker D, Aggarwal N, Arcila-Galvis JE, Ashrafiyan S, Baumgarten N, Ardakani FB, Branco Lins PR, Breeze CE, Brownlee D, Bujold D, Chapman AR, Chow SH, Dincer TU, Dupras C, Frosi G, Fu J, Gérard D, Hauduc A, Hyacinthe J, Jaroszewicz A, Li R, Mangan RJ, Mikulasova A, Moghul I, Needhamsen M, Palmour N, Pacheco MP, Quon J, Raby J, Reynolds A, Rumpf L, Salhab A, Shi CH, Sinkkonen L, Tanigawa Y, Tanner RM, Vu H, White F, Aw JTM, Badii S, Bowlby R, Boyle M, Brown C, Chand D, Calingo M, Cao Q, Carles A, Caron M, Carreira M, Cheng ASL, Cheng CCY, Cheng D, Cheng Y, Cheung MF, Choe G, Chuah E, Dali R, Deng A, Gakkhar S, Gut M, He A, Heath SC, Ho V, Intan AG, Ito CY, Jiang Q, Kluiver JL, Lee J, Lee S, Leung Z, Li I, Lorzadeh A, McKerricher D, Mishra N, Mungall K, Nagai LAE, Ngubo M, Palmquist D, Pang J, Park V, Plettner P, Puri A, Redensek A, Sharafian Z, Simon MM, Steif J, Su E, Tam SKM, Tam SST, Van den Berg A, Wong R, Wong T, Wu JKH, Zhu A, Kwan T, Moksa M, Aherne ST, Aparicio S, Arima T, Chung HR, Costello JF, Eaves CJ, Fisher SJ, Gut IG, Harrison PW, Horsthemke B, Ilsley GR, Jagodic M, Karsan A, Lavoie PM, Leung D, Libbrecht MW, Manke T, Marra MA, Meuleman W, Müller F, Nakato R, Okae H, Rico D, Rosenstiel P, Sasaki H, Sauter T, Schreiber S, Scott DW, Stanford WL, Steidl C, Stunnenberg HG, Suyama M, Tran F, Ushijima T, Weng AP, Wiseman SM, Wu AR, Yip KY, Yip S, Beck S, Bourque G, Ernst J, Jacques PÉ, Joly Y, Kellis M, List M, Perkins TJ, Schulz MH, Walter J, Hirst M

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.06.22.729579 PMID: 42395464

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Hilton LK, Gillis S, Y-Moayyed F, Bridgers J, Alduaij W, Jiang A, Ben-Neriah S, Collinge B, Wong JCH, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Villa D, Savage KJ, Sehn LH, Karsan A, Wright GW, Staudt LM, Morin RD, Steidl C, Scott DW

Blood advances2026

DOI: 10.1182/bloodadvances.2026020105 PMID: 41985007

A Living Archive of High-risk Lymphoma.

Evgin L, Steidl C

Blood cancer discovery2026Senior author

DOI: 10.1158/2643-3230.bcd-26-0250 PMID: 42573271

LCR-modules: a collection of workflows for cancer genome analysis.

Dreval K, Hilton LK, Grande BM, Banco G, Coyle KM, Cruz M, Gillis S, Klossok L, Pararajalingam P, Rushton CK, Shaalan H, Thomas N, Winata H, Wong J, Yiu J, Steidl C, Scott DW, Morin RD

Bioinformatics (Oxford, England)2026

DOI: 10.1093/bioinformatics/btag366 PMID: 42271624

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Aoki T, Duns G, Rai S, Jiang A, Lytle A, Yin Y, Kishida M, Yu Li M, Lee C, Smorra D, Hilton LK, Healy S, Alig SK, Shahrokh Esfahani M, Sarkozy C, Hung SS, Milne K, Telenius A, O'Brien L, Wong JCH, Cassidy C, Fujisawa M, Strong C, Goodyear T, Di Vito C, Luksik C, Edin G, Gonzalez L, Rangel Patiño J, Hong M, Wu S, Lee E, Sakhdari A, Takata K, Miyata-Takata T, Boyle M, Ben-Neriah S, Weng AP, Xu A, Merchant A, Roth A, Crump M, Kuruvilla J, Prica A, Kridel R, Huntsman DG, Nelson BH, Farinha P, Morin RD, Alizadeh AA, Savage KJ, Scott DW, Steidl C

Cancer discovery2026Senior author

DOI: 10.1158/2159-8290.cd-25-0859 PMID: 41615883

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS

Blood2026

DOI: 10.1182/blood.2025029546 PMID: 41662628

IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.

Zhang HF, De Dreuzy E, Huang YZ, Shin S, Huang QF, Delaidelli A, Yang X, Adamiak V, Lytle A, Arzoo A, Lizardo MM, Lin Q, Sanadi S, Rouleau M, Liu LX, Xu LY, Li EM, Lai R, Primus C, Reda El Sayed S, Bourhis L, Genin D, Demontrond L, Bouquet L, Labarthe Démolis L, Barberot A, Lameynardie S, Delabrière A, Hua H, Yang J, Ishima R, Imle R, Banito A, Slack GW, Savage KJ, Maris JM, Bosse KR, Dimitrov DS, Steidl C, Li W, Sainson RCA, Sorensen PH

Cancer discovery2026

DOI: 10.1158/2159-8290.cd-25-1036 PMID: 41973074

Aging cells, young patients: senescence in Hodgkin lymphoma.

Kong IY, Giulino-Roth L, Steidl C

Blood advances2026Senior author

DOI: 10.1182/bloodadvances.2025019439 PMID: 41996198

Something wrong or missing on this profile? Suggest a correction

Christian Steidl

Research

Latest papers

Latest funding

Non-canonical NF-&#x3ba;B drives a fate switch from germinal center to early effector B cells.

HNRNPU mutations redirect cell cycle control to E2F in MYC-driven lymphomas.

EpiATLAS - a reference for human epigenomic research.

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

A Living Archive of High-risk Lymphoma.

LCR-modules: a collection of workflows for cancer genome analysis.

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.

Aging cells, young patients: senescence in Hodgkin lymphoma.

Frequent collaborators

Robert Kridel

Aly Karsan

Jan Delabie

Leandro Venturutti

Ali Bashashati

John Kuruvilla

Samuel Aparicio

Martin Hirst

Jiarui Ding

Laura Evgin

Marco Marra

Wei Xu

Sohrab Shah

Steven Jones

Arman Rahmim

Wan Lam

Andrew Weng

David Lebrun

Peter Watson

Dean Regier

Sonia Del Rincon

Aline Talhouk

Peter Unrau

Carl Hansen

Sheila Singh

Cynthia Hawkins

Michael Gold

Carolyn Brown

David Huntsman

Non-canonical NF-κB drives a fate switch from germinal center to early effector B cells.